MAIA Biotechnology, Inc. filed a Current Report on Form 8-K with the Securities and Exchange Commission on October 6, 2026. The filing was submitted by the registrant, which is incorporated in Delaware and has its principal executive offices located at 444 West Lake Street, Suite 1700, Chicago, IL 60606.
The report indicates that the company has prepared a presentation and a summary document intended for use in future communications regarding its operations and performance. Both documents were posted to the company's website on the same date as the filing.
The presentation and the summary are furnished as Exhibits 99.1 and 99.2, respectively. The company notes that the information contained in these documents is summary information and should be considered in the context of its filings with the SEC and other public announcements.
The filing includes a standard forward-looking statement disclaimer. MAIA Biotechnology cautions that all statements other than historical facts are forward-looking and subject to risks and uncertainties, including the initiation, timing, cost, progress, and results of clinical studies and research programs, as well as the ability to advance product candidates and obtain regulatory approvals.
The company undertakes no obligation to publicly update or revise any forward-looking statements contained in the filing.
